Artivila Biopharma Announces Over RMB 100 Million Pre-A+ Financing to Advance AI-Driven Drug Discovery Platform and Pipeline Expansion

VCBeat (WeChat ID: vcbeat) has learned that on March 31, 2022, Artivila Biopharma (Shenzhen) Co., Ltd. (“Artivila Biopharma”) announced the completion of its Pre-A+ financing round, raising over RMB 100 million. The round was led by Jianyi Capital (formerly Sinopharm Capital), with continued support from existing investors including Honghui Fund, Bopu Capital, and Shanxing Capital. The proceeds will be used to build an AI platform for new drug research and development, advance and expand the company’s pipeline, and support corporate operations and international business development.

Kehui Pharma was co-founded by two senior experts and R&D executives in the biopharmaceutical industry. Its core R&D team members possess many years of research and development experience in the U.S. biopharmaceutical sector. Kehui Pharma focuses on innovative drug development, striving to become an AI-driven R&D-focused innovative pharmaceutical company. Guided by clinical benefits for patients, the company is deeply engaged in areas with significant unmet medical needs, such as neuroscience, autoimmune diseases, and oncology, to explore novel therapies.

Dr. Zhu Zhendong, Founder and Chairman of Kehui Zhiyao, and Niu Deqiang, Co-founder and CEOPh.D. Co-founderstated: “Over the past 12 months, Kechuang Zhiyao has successfully completed two rounds of financing, raising a total of nearly RMB 300 million. We are deeply grateful to both new and existing investors for their recognition and support of Kechuang Zhiyao. Since 2021, the company and its team have experienced rapid growth, with significant progress made in platform development and pipeline advancement. We remain committed to our mission and will continue striving to change the fate of patients.”

Lin Tao, Managing Director of Sinopharm Capital, and Dr. Zhao Han, Vice President of Investmentstating: “The integration of computational chemistry/AI with new drug development is gaining momentum. We highly value the capacity of this tool to raise the ceiling of new drug R&D, and look forward to its playing a greater role in high-difficulty, high-value pipelines. As an innovative pharmaceutical company combining an AI R&D platform with ‘First-in-Class’ pipelines, Kehui Zhiyao embeds its AI platform into the Biotech R&D chain, adheres to clinical value orientation, and pursues an internationalized path of original R&D. We strongly endorse Kehui Zhiyao’s development philosophy and look forward to collaborating closely with the company to foster mutual growth, support its internationalization strategy, and deliver better treatment options to patients at an earlier date.””

Shanghai Jianyi Private Equity Fund Management Co., Ltd. (formerly Sinopharm Capital) was established in 2012 by the senior management team of the former Sinopharm Group, operating under market-oriented mechanisms. It combines the strategic investment advantages of a Corporate Venture Capital (CVC) firm with the market-driven strengths of an independent Venture Capital (VC) fund, focusing on early-stage and growth-stage equity investments in the pharmaceutical and healthcare sectors. Leveraging its extensive industrial resources to empower portfolio companies, Jianyi Capital has managed funds exceeding RMB 6.5 billion since its inception. Its investment portfolio comprehensively covers early-stage innovative ventures, growth-stage companies, and merger and acquisition integration projects. In the broader healthcare sector, Jianyi Capital has invested in nearly 80 standout enterprises, including Sinopharm Dental, Funuojian Biotechnology, Chengyi Biopharma, Linko Pharmaceuticals, GenFleet Therapeutics, Senyi Intelligence, Sepax Technologies, Aide Technology, Juyi Technology, Xintong Medicine, and ClearMed Biotech. The firm has successfully achieved multiple initial public offerings (IPOs) for companies such as Aier Eye Hospital’s subsidiary Aibo Medical, Yhlo Biotech, Allist Pharmaceuticals, and Anbo Biology. Adhering to the philosophy of “Sincerity, Professionalism, and Win-Win Cooperation,” Jianyi Capital remains committed to growing alongside its portfolio companies.

Founded in late 2018, the company is an innovative pharmaceutical R&D enterprise dedicated to improving patients’ lives through an AI-driven drug discovery engine. Committed to building a robust and efficient drug discovery technology platform, it focuses on drug development for neurodegenerative diseases, autoimmune disorders, and oncology, aiming to provide patients with optimal therapeutic regimens.